WOMEN AND INFANTS TRANSMISSION STUDY--CHICAGO

WITS是一项关于围产期HIV感染的开创性研究。它具有广泛的 从大量艾滋病毒感染者中寻求深入信息的议程 妇女和她们的婴儿。 目前的芝加哥WITS-I小组包括 伊利诺伊大学芝加哥分校、西北大学、儿童 纪念医院和库克县医院。芝加哥队的队员们 为研究的科学合作议程作出了贡献， 制定在全国开展研究的程序， 以及当地，并在具体的协议和 传播成果。 他们还获得了其他赠款支持， 基础科学和流行病学研究以及临床试验， 与WITS互动并扩大其范围。 到1992年12月，芝加哥研究中心共招募了116名HIV感染孕妇， 39名未怀孕的艾滋病毒感染妇女和79名婴儿。在过去 西北大学（包括儿童纪念医院）和 库克县医院开始招募参与者。为过去6 月，平均芝加哥入学率平均每月5.2或62 每一年。芝加哥还提议增加芝加哥大学作为 WITS-II的另一个网站。因此保守估计 WITS-II第一年的入学人数为75人，不考虑 导致血清阳性率上升。HIV感染的血清阳性率 在伊利诺伊州的匿名新生儿调查中， 1992年比前一年增长了52%。虽然芝加哥一直是 中度血清阳性率地区，这些数字表明， 围产期艾滋病毒感染的流行。芝加哥WITS网站将在 监测这一流行病不断变化的动态的独特地位。 芝加哥集团将继续贡献优质数据和创新 想法. 94%的研究访视按时完成，91%的参与者 最初入组的患者继续参与研究，超过92%的患者 病史、体格检查和人口统计表填写完整，或 很快就会竞争。超过90%的指定实验室研究 其中HIV培养物占91%，淋巴细胞占92 表型研究。为了提高WITS-II的科学价值， 芝加哥团队提出了几个发展研究主题， WITS的核心目标。 这些包括检查HLA抗原，TH 1/TH 2 淋巴细胞“平衡”、细胞凋亡和合胞体形成病毒分离物， 垂直传播或疾病快速进展的风险。其他 研究将通过原位PCR检测胎儿组织中的病毒， 母胎病毒包膜序列，以更好地确定阶段 怀孕期间发生感染。此外，该组织建议， 研究在孕妇中进行疫苗研究的可行性。 这些发展研究课题直接关系到具体的目标 并利用已有的数据和样本或 可以很容易地纳入WITS-II协议。 拟议的计划将继续芝加哥小组在WITS-II中的工作。 的创新特点、工作质量和效率， 小组将提高WITS-II的总体科学生产力。

WITS is a seminal study of perinatal HIV infection. It has a wide-ranging agenda seeking in-depth information from a large cohort of HIV infected women and their infants. The current Chicago WITS-I group includes the University of Illinois at Chicago, Northwestern University, Children's Memorial Hospital and Cook county Hospital. Chicago team members have contributed to the scientific collaborative agenda of the study, the development of procedures for the execution of the study nationally as well as locally, and have provided leadership in specific protocols and dissemination of results. They have also received other grant support for basic scientific and epidemiologic studies and clinical trials that interact with WITS and extends its scope. Through December 1992, the Chicago site enrolled 116 pregnant HIV infected women, 39 non-pregnant HIV infected women, and 79 infants. During the last year Northwestern University (including Children's Memorial Hospital) and Cook County Hospital started enrolling participants. For the last 6 months, the average Chicago enrollment has averaged 5.2 per month or 62 per year. Chicago also proposes adding University of Chicago as an additional site for WITS-II. Therefore, it is conservatively estimated that enrollment for year 1 of WITS-II will be 75, without taking into account an increase in seroprevalence. The seroprevalence of HIV infection in pregnancy by anonymous newborn survey in the State of Illinois increased 52% 1992 over the preceding year. Although Chicago has been a moderate seroprevalence area, these figures suggest an important surge in the epidemic of perinatal HIV infection. The Chicago WITS site will be in a unique position of monitoring the changing dynamics of the epidemic. The Chicago group will continue to contribute quality data and innovative ideas. 94% of study visits were completed on time, 91% of participants originally enrolled have continued in the study, and greater than 92% of historical, physical examination and demographic forms are complete or will be competed shortly. More than 90% of indicated laboratory studies were obtained, including 91% of HIV cultures and 92% of lymphocyte phenotyping studies. To enhance the scientific value of WITS-II, the Chicago team proposes several developmental research topics that address central aims of WITS. These include examination of HLA antigens, TH1/TH2 lymphocyte "balance", apoptosis and syncytium forming viral isolates on the risk of vertical transmission or rapid disease progression. Other studies will examine virus in fetal tissue by in situ PcR and compare maternal-fetal viral envelope sequences to better define the stage of pregnancy at which infection occurs. In addition, the group proposes examining the feasibility of doing vaccine studies in pregnant women. These developmental research topics relate directly to the specific aims of WITS and make use of data and samples already available or samples that can be readily incorporated into the WITS-II protocol. The proposed plan will continue the work of the Chicago team in WITS-II. The innovative characteristics, quality of work and efficiency of the group will enhance the overall scientific productivity of WITS-II.